World News

The deal comes as pharmaceutical companies increase investment in therapies that target RAS, a family of proteins involved in regulating cell growth and division.

The companies have also signed a non-binding MoU covering a broader global programme to evaluate ivonescimab in combination with additional AstraZeneca oncology therapies.

The development of Accela and NeoArc involved collaboration with an advisory group comprising several cancer research and treatment institutions.

Merck plans to present the BRUNELLO results at the American Academy of Ophthalmology Annual Meeting in New Orleans on October 10 and discuss the findings with regulatory authorities.

The approval is based on Lilly’s QWINT Phase III clinical programme, which evaluated insulin efsitora alfa-gobe in more than 3,400 adults with T2D across four registration studies.

The agreement comes as Novo continues to strengthen its position in cardiometabolic medicines, where longer dosing intervals are a growing focus of research and development.

The approval gives AbbVie another Parkinson’s product following its acquisition of Cerevel Therapeutics.

The withdrawal changes the immediate US regulatory path for the ES-SCLC indication, but the ongoing Phase III programme provides the companies with another source of clinical data.

The CE-IVDR-certified test is designed to detect three diabetes-associated autoantibodies (AAbs) that can indicate an increased risk of developing T1D.

Anaconda is targeting the large vessel occlusion stroke market, where mechanical thrombectomy is used to remove blood clots from blocked cerebral arteries.